Articles related to RESEARCH & CLINICAL TRIALS

Rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to those for low-dose aspirin, whereas rates were higher for rivaroxaban.

This study demonstrated that luteolin, a natural antioxidant, can suppress hair graying in model mice. Our findings suggest that luteolin could be a viable candidate for developing therapeutic interventions aimed at maintaining original hair color.

“…three drugs were associated with more negative or failed efficacy trials than positive ones…”

Results of multiple clinical trials demonstrate that SYMBRAVO can provide rapid and long-lasting freedom from migraine pain, whether treatment is taken early in the attack while the pain is mild, or later in the attack when the pain may be severe.

The emergence of novel agents including BTK degraders, next-generation BCL2 inhibitors, and optimized combination approaches is reshaping the CLL treatment landscape, with multiple trials demonstrating high uMRD rates, improved progression-free survival, and manageable toxicity profiles across different patient populations.

Flow cytometric evaluation of MRD in AML demonstrates that blast phenotypes consistently show abnormalities but may evolve during treatment, emphasizing the importance of comprehensive antigen panel analysis for accurate detection.